Olema Pharmaceuticals Management
Management criteria checks 2/4
Olema Pharmaceuticals' CEO is Sean Bohen, appointed in Sep 2020, has a tenure of 3.58 years. total yearly compensation is $5.99M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $1.42M. The average tenure of the management team and the board of directors is 3.6 years and 3.7 years respectively.
Key information
Sean Bohen
Chief executive officer
US$6.0m
Total compensation
| CEO salary percentage | 10.3% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.6yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$97m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$97m |
| Mar 31 2023 | n/a | n/a | -US$110m |
| Dec 31 2022 | US$6m | US$616k | -US$105m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$95m |
| Mar 31 2022 | n/a | n/a | -US$79m |
| Dec 31 2021 | US$3m | US$595k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$60m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$11m | US$178k | -US$24m |
Compensation vs Market: Sean's total compensation ($USD5.99M) is above average for companies of similar size in the US market ($USD2.37M).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
CEO
Sean Bohen (56 yo)
3.6yrs
Tenure
US$5,989,638
Compensation
Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$5.99m | 0.26% $ 1.4m | |
| Chief Operating & Financial Officer | 3.8yrs | US$2.27m | 0.87% $ 4.8m | |
| Chief Medical Officer | 2.3yrs | US$2.25m | 0.14% $ 790.0k | |
| Vice President of Investor Relations & Communications | less than a year | no data | no data | |
| Senior VP & Head of People | no data | no data | no data | |
| Chief Discovery & Non-Clinical Development Officer | 3.8yrs | US$200.00k | 1.33% $ 7.3m | |
| VP & Head of Clinical Pharmacology | no data | no data | no data | |
| Corporate Secretary | 3.6yrs | US$3.27m | no data | |
| VP of Finance & Controller | 1.3yrs | no data | no data |
3.6yrs
Average Tenure
55yo
Average Age
Experienced Management: OLMA's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$5.99m | 0.26% $ 1.4m | |
| Independent Director | 11.3yrs | US$106.94k | 0.69% $ 3.8m | |
| Independent Director | 3.7yrs | US$114.94k | 0.15% $ 824.5k | |
| Independent Chairperson of the Board | 3.7yrs | US$134.94k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 3yrs | US$11.81k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.4yrs | US$92.94k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$105.94k | 0% $ 0 | |
| Independent Director | 3yrs | US$97.94k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$102.94k | 0% $ 0 | |
| Director | 17.7yrs | no data | 1.7% $ 9.3m |
3.7yrs
Average Tenure
62yo
Average Age
Experienced Board: OLMA's board of directors are considered experienced (3.7 years average tenure).